WO2002079231B1 - Nucleic acids encoding isav polypeptides - Google Patents
Nucleic acids encoding isav polypeptidesInfo
- Publication number
- WO2002079231B1 WO2002079231B1 PCT/US2002/009681 US0209681W WO02079231B1 WO 2002079231 B1 WO2002079231 B1 WO 2002079231B1 US 0209681 W US0209681 W US 0209681W WO 02079231 B1 WO02079231 B1 WO 02079231B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- nucleic acid
- acid sequence
- salmon
- fish
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract 56
- 108020004707 nucleic acids Proteins 0.000 title claims abstract 32
- 102000039446 nucleic acids Human genes 0.000 title claims abstract 32
- 229920001184 polypeptide Polymers 0.000 title claims abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 8
- 241000251468 Actinopterygii Species 0.000 claims abstract 15
- 235000019688 fish Nutrition 0.000 claims abstract 15
- 241001465754 Metazoa Species 0.000 claims abstract 12
- 241000546112 Infectious salmon anemia virus Species 0.000 claims abstract 11
- 230000028993 immune response Effects 0.000 claims abstract 10
- 230000009261 transgenic effect Effects 0.000 claims abstract 9
- 230000000890 antigenic effect Effects 0.000 claims abstract 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 241000972773 Aulopiformes Species 0.000 claims 4
- 235000019515 salmon Nutrition 0.000 claims 4
- 241000881711 Acipenser sturio Species 0.000 claims 3
- 241000473391 Archosargus rhomboidalis Species 0.000 claims 3
- 241000723298 Dicentrarchus labrax Species 0.000 claims 3
- 241001417899 Oncorhynchus clarkii Species 0.000 claims 3
- 241000277329 Oncorhynchus keta Species 0.000 claims 3
- 241000277338 Oncorhynchus kisutch Species 0.000 claims 3
- 241000131739 Oncorhynchus masou rhodurus Species 0.000 claims 3
- 241000277275 Oncorhynchus mykiss Species 0.000 claims 3
- 241000277277 Oncorhynchus nerka Species 0.000 claims 3
- 241001280377 Oncorhynchus tshawytscha Species 0.000 claims 3
- 241000269908 Platichthys flesus Species 0.000 claims 3
- 241000277263 Salmo Species 0.000 claims 3
- 241000277288 Salmo trutta Species 0.000 claims 3
- 241000277293 Salvelinus alpinus Species 0.000 claims 3
- 241000277284 Salvelinus fontinalis Species 0.000 claims 3
- 241000276707 Tilapia Species 0.000 claims 3
- 241001233037 catfish Species 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000013604 expression vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Infectious Salmon Anemia Virus (ISAV) nucleic acid molecules and polypeptides are disclosed, as well as host cells and transgenic fish transformed by expression vectors containing such nucleic acids. The nucleic acid molecules can encode antigenic epitopes capable of eliciting an immune response in a host cell or animal, such as an immune response against ISAV, and the polypeptides themselves can be antigenic epitopes and also induce such an immune response.
Claims
AMENDED CLAIMS
[received by the International Bureau on 13 May 2003 (13.05.03); original claims 1-7, 12-16 and 19-27 amended; new claims 34-35 added; remaining claims unchanged (6 pages)]
WE CLAIM
1. A pharmaceutical composition comprising a therapeutically effective amount of an isolated nucleic acid molecule in a pharmaceutically acceptable carrier, wherein the isolated nucleic acid molecule comprises at least one of (a) a nucleic acid sequence at least 70% identical to SEQ ID NO: 1; (b) a nucleic acid sequence at least 85% identical to SEQ ID NO: 3; (c) a nucleic acid sequence at least 85% identical to SEQ ID NO: 11; (d) a nucleic acid at least 80% identical to SEQ ID NO; 5; or (e) a nucleic acid at least 80% identical to SEQ ID NO: 9, and wherein the pharmaceutical composition can be used to induce an immune response to ISAV.
2. The pharmaceutical composition according to claim 34, wherein the nucleic acid sequence is at least 80% identical to SEQ ID NO: 5.
3. The pharmaceutical composition according to claim 34, wherein the nucleic acid sequence is at least 90% identical to SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 11.
4. The phartnaceutical composition according to claim 34, wherein the nucleic acid sequence is at least 95% identical to SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 11.
5. The pharmaceutical composition according to claim 34, wherein the nucleic acid sequence consists essentially of SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 11.
6. The pharmaceutical composition according to claim 34, wherein the nucleic acid sequence is operably linked to a heterologous nucleic acid comprising an expression control sequence.
AMENDED SHEET (ARTICLE 19) 44
7. The pharmaceutical composition according to claim 6, wherein the nucleic acid molecule encodes an antigenic epitope.
8. A vector comprising the nucleic acid molecule according to claim 6.
9. A host cell, comprising the nucleic acid according to claim 6.
10. The host cell according to claim 9, wherein the cell is a fish cell
11. The host cell according to claim 10, wherein the fish cell is from rainbow trout, coho salmon, chinook salmon, amago salmon, chum salmon, sockeye salmon, Atlantic salmon, arctic char, brown trout, cutthroat trout, brook trout, catfish, tilapia, sea bream, seabass, flounder, or sturgeon.
12. An isolated nucleic acid comprising at least 100 consecutive nucleotides of SEQ ID NO: 5.
13. A transgenic animal, a nucleated cell of which comprises: an expression control sequence operably linked to a nucleic acid molecule comprising (a) a nucleic acid sequence at least 70% identical to SEQ ID NO: 1; (b) a nucleic acid sequence at least 85% identical to SEQ ID NO: 3; (c) a nucleic acid sequence at least 85% identical to SEQ ID NO: 11; (d) a nucleic acid at least 80% identical to SEQ ID NO: 5; or (e) a nucleic acid at least 80% identical to SEQ ID NO: 9, and wherein the pharmaceutical composition can be used to induce an immune response to ISAV; wherein the nucleic acid sequence encodes an antigenic epitope.
14. The transgenic animal according to claim 35, wherein the animal exhibits an increased resistance to infection by infectious salmon anemia virus as compared to a non-transformed animal of the same species.
AMENDED SHEET (ARTICLE 19) 45
15. The transgenic animal according to claim 35, wherein the animal is an aquacultuxe animal.
16. The transgenic animal according to claim 35, wherein the animal is a fish.
17. The transgenic animal according to claim 16, wherein me fish is rainbow trout, coho salmon, chinook salmon, amago salmon, chum salmon, sockeye salmon, Atlantic salmon, arctic char, brown trout, cutthroat trout, brook trout, catfish, tilapia, sea bream, seabass, flounder, or sturgeon.
18. A method of eliciting an immune response against infections salmon anemia virus in a fish, comprising introducing into the fish a therapeutically effective amount of the nucleic acid molecule according to claim 6, wherein the nucleic acid molecule encodes an antigenic epitope of infectious salmon anemia virus, thereby eliciting an immune response against infectious salmon anemia virus in the fish.
1 . The method according to claim 18, wherein the nucleic acid molecule has a nucleic acid sequence at least 80% identical to SEQ ID NO: 5.
20. The method according to claim 19, wherein the nucleic acid molecule has a nucleic acid sequence at least 85% identical to SEQ ID NO: 5.
21. The method according to claim 20, wherein the nucleic acid molecule has a nucleic acid sequence at least 90% identical to SEQ ID NO: 5.
AMENDED SHEET (ARTICLE 19) 46
22. The method according to claim 21 , wherein the nucleic acid molecule has a nucleic acid sequence at least 95% identical to SEQ ID NO: 5.
23. The method according to claim 22, wherein the nucleic acid molecule has a nucleic acid sequence consisting essentially of SEQ ID NO: 5.
24. The method according to claim 18, wherein the nucleic acid sequence is at least 90% identical to SEQ ID NO: 9 oτ SEQ ID NO: 11.
25. The method according to claim 24, wherein the nucleic acid sequence is at least 95% identical to SEQ ID NO: 9 or SEQ ID NO: 11.
26. The method according to claim 25, wherein the nucleic acid sequence is at least 95% identical to SEQ ID NO: 9 or SEQ ID NO: 11.
27. The method according to claim 26, wherein the nucleic acid sequence consists essentially of SEQ fD NO; 9 or SEQ ID NO: 11.
28. A method of producing a transgenic fish, comprising contacting a nucleated cell of the fish with an amount of the nucleic acid molecule according to claim 6, wherein the amount of the nucleic acid molecule is sufficient to introduce the nucleic acid molecule into the cell, thereby producing a transgenic fish.
29. The method according to claim 28, wherein the fish is rainbow trout, coho salmon, chinook salmon, amago salmon, chum salmon, sockeye salmon, Atlantic salmon, arctic char, brown trout, cutthroat trout, brook trout, catfish, tilapia, sea bream, seabass, flounder, or sturgeon.
30. A polypeptide encoded by the nucleic acid molecule according to claim 1, or a conservative variant thereof.
31. A method of inducing an immune response in a fish, comprising: dehVering to the fish a fherapeuticaϋy effective amount of a composition comprising a polypeptide having an aroino acid sequence as set forth as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO; 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 18, an antigenic fragment thereof, or a conservative variant thereof; and wherein the polypeptide is an antigenic epitope of infectious salmon anemia virus, thereby eHciting an immune response against infectious salmon anemia virus in the fish.
32. The method according to claim 31 wherein the polypeptide has an amino acid sequence consisting essentially of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 18
33. The method according to claim 31 wherein the polypeptide comprises a fusion protein.
34. The pharmaceutical composition of claim 1, comprising at least one of (a) a nucleic acid sequence at least 85% identical to SEQ ID NO: 11, (b) a nucleic acid at least 80% identical to SEQ ID NO: 5, and (c) a nucleic acid at least 80% identical to SEQ ID NO; 9.
35. A transgenic animal of cl aim 16, comprising an expression control sequence operably linked to a nucleic acid molecule comprising at least one of (a) a nucleic acid sequence at least 85% identical to SEQ ID NO: 11, (b) a nucleic acid at least 80% identical to SEQ ID NO: 5, or (c) a nucleic acid
AMENDED SHEET (ARTICLE 19) 48
at least 80% identical to SEQ ID NO: 9, and wherein the pharmaceutical composition can be used to induce an immune response to ISAV; wherein the nucleic acid sequence encodes an antigenic epitope.
AMENDED SHEET (ARTICLE 19) 49
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002254427A AU2002254427A1 (en) | 2001-03-30 | 2002-03-29 | Nucleic acids encoding isav polypeptides |
| US10/472,990 US20040147467A1 (en) | 2002-03-29 | 2002-03-29 | Nucleic acids encoding isav polypeptides |
| CA2442346A CA2442346C (en) | 2001-03-30 | 2002-03-29 | Nucleic acids encoding isav polypeptides |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28054501P | 2001-03-30 | 2001-03-30 | |
| US60/280,545 | 2001-03-30 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2002079231A2 WO2002079231A2 (en) | 2002-10-10 |
| WO2002079231A3 WO2002079231A3 (en) | 2003-12-18 |
| WO2002079231B1 true WO2002079231B1 (en) | 2004-02-19 |
Family
ID=23073544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2002/009681 WO2002079231A2 (en) | 2001-03-30 | 2002-03-29 | Nucleic acids encoding isav polypeptides |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2002254427A1 (en) |
| CA (1) | CA2442346C (en) |
| WO (1) | WO2002079231A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7279167B2 (en) | 2001-10-19 | 2007-10-09 | Intervet International B.V. | Infectious Salmon Anaemia virus vaccine |
| US20130243803A1 (en) * | 2012-03-09 | 2013-09-19 | Samuel Bogoch | Therapies, vaccines, and predictive methods for infectious salmon anemia virus |
| WO2024055123A1 (en) * | 2022-09-16 | 2024-03-21 | Gmg Fish Services Inc. | Vaccines against infectious salmon anemia and uses thereof |
-
2002
- 2002-03-29 AU AU2002254427A patent/AU2002254427A1/en not_active Abandoned
- 2002-03-29 WO PCT/US2002/009681 patent/WO2002079231A2/en not_active Application Discontinuation
- 2002-03-29 CA CA2442346A patent/CA2442346C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002079231A2 (en) | 2002-10-10 |
| CA2442346A1 (en) | 2002-10-10 |
| AU2002254427A1 (en) | 2002-10-15 |
| WO2002079231A3 (en) | 2003-12-18 |
| CA2442346C (en) | 2016-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2395499A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| WO2006116763A3 (en) | Lawsonia intracellularis immunological proteins | |
| CN100378124C (en) | Hsp70 from arthrobacter | |
| WO2002079231B1 (en) | Nucleic acids encoding isav polypeptides | |
| KR100207354B1 (en) | Recombinant coccidiosis vaccines-5-7-eimeria surface antigen and a method for protecting poultry against coccidiosis using the same | |
| US5942413A (en) | Nematode vaccine | |
| EP1334197B1 (en) | Yeast derived vaccine against ipnv | |
| Jaso-Friedmann et al. | The antigen receptor (NCCRP-1) on catfish and zebrafish nonspecific cytotoxic cells belongs to a new gene family characterized by an F-box-associated domain | |
| Padmalayam et al. | The 75-kilodalton antigen of Bartonella bacilliformis is a structural homolog of the cell division protein FtsZ | |
| Yasuda et al. | The complete amino acid sequence of growth hormone from sturgeon (Acipencer guldenstadti) | |
| CA2353802A1 (en) | New protective antigen of group a streptococci | |
| CN1626544A (en) | Expressing Ompk antigen of outer-membrane protein of Vibrio Harveyi and application as constituent of bacterin | |
| WO1994010316B1 (en) | Actinobacillus pleuropneumoniae outer membrane lipoprotein a and uses thereof | |
| CN108779152B (en) | Insoluble fusion protein comprising antimicrobial peptide and method for producing antimicrobial peptide using same | |
| JP2002538775A5 (en) | ||
| US6642032B2 (en) | Uses of avian interferon gamma (IFN-γ) | |
| DK200900603A (en) | Piscirickettsia salmonis antigens and their use | |
| US5366728A (en) | Stable forms of antigenic Taenia ovis polypeptides | |
| CA2402339A1 (en) | Viral antigen and vaccine against isav (infectious salmon anaemia virus) | |
| Albrecht et al. | Expression of CaMV ORF IV in Escherichia coli | |
| CN111732640A (en) | Recombinant vibrio anguillarum OmpA protein and preparation method and application thereof | |
| JPH04305599A (en) | Prolactin | |
| CN1576367A (en) | Prawn leukasmus rhabdovirus WP486 gene and coded polypeptide thereof | |
| CN1629290A (en) | A shrimp gene PIAV and polypeptides coded thereby | |
| CN1629291A (en) | A shrimp gene Intlp and polypeptides coded thereby |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 10472990 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2442346 Country of ref document: CA |
|
| B | Later publication of amended claims |
Effective date: 20030513 |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |